Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

Planned Kevetrin trials:

1. Ovarian – single agent and in combo, phase 2, orphan status

2. Pancreatic – single agent, phase 2, orphan status and research grant applied

3. AML – single agent and in combo with cytarabine, phase 2, paid for by University of Bologna

4. Renal – in combo with a tyronsine kinase inhibitor, phase 2, possible Specialized Programs of Research Excellence (SPORE) grant

5. Retinoblastoma – single agent, phase 2, possible Pediatric Disease Priority Review Voucher (PPRV)